Cytosorbents (CTSO) Shareholder's Equity Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.95% |
| Dec 31, 2025 | -40.51% |
| Sep 30, 2025 | -35.41% |
| Jun 30, 2025 | -13.78% |
| Mar 31, 2025 | -7.36% |
| Dec 31, 2024 | 26.58% |
| Sep 30, 2024 | 14.73% |
| Jun 30, 2024 | 8.59% |
| Mar 31, 2024 | 5.50% |
| Dec 31, 2023 | 6.75% |
| Sep 30, 2023 | -1.29% |
| Jun 30, 2023 | 2.56% |
| Mar 31, 2023 | 15.69% |
| Dec 31, 2022 | 28.08% |
| Sep 30, 2022 | 32.81% |
| Jun 30, 2022 | 43.14% |
| Mar 31, 2022 | 106.21% |
| Dec 31, 2021 | 115.79% |
| Sep 30, 2021 | 119.72% |
| Jun 30, 2021 | 80.37% |
| Mar 31, 2021 | 65.28% |
| Dec 31, 2020 | 51.74% |
| Dec 31, 2019 | -13.22% |
| Sep 30, 2019 | 21.28% |
| Jun 30, 2019 | 26.59% |
| Mar 31, 2019 | 32.40% |
| Dec 31, 2018 | 26.09% |
| Sep 30, 2018 | 28.29% |
| Jun 30, 2018 | 29.45% |
| Mar 31, 2018 | 26.27% |
| Dec 31, 2017 | 23.58% |
| Sep 30, 2017 | 51.36% |
| Jun 30, 2017 | 67.97% |
| Mar 31, 2017 | -37.61% |
| Dec 31, 2016 | 16.35% |
| Sep 30, 2016 | 4.23% |
| Jun 30, 2016 | 15.24% |
| Dec 31, 2015 | 26.36% |